<DOC>
	<DOCNO>NCT00484926</DOCNO>
	<brief_summary>The purpose REAL-LATE ( Correlation Clopidogrel Therapy Discontinuation REAL-world Patients Treated Drug-Eluting Stent Implantation Late Coronary Arterial Thrombotic Events ) trial ass relationship clopidogrel use long-term rate cardiac death MI DES implantation real-world practice estimate duration dual antiplatelet therapy prevent late thrombotic event .</brief_summary>
	<brief_title>Association Clopidogrel Therapy Stent Thrombosis</brief_title>
	<detailed_description>An observational analysis BASKET-LATE ( Basel Stent Kosten-Effekivitats Trial-Late Thrombotic Events ) examine incidence clinical event cessation clopidogrel therapy . This study identify 746 patient without major adverse event 6 month drug-eluting bare-metal stent placement . All patient stop take clopidogrel follow additional 12 month . At 18-month follow-up , difference patient drug-eluting bare-metal stent cumulative rate death myocardial infarction ( MI ) . However , clopidogrel discontinuation patient receive drug-eluting vs bare-metal stent experience high rate death MI ( 4.9 % vs 1.3 % , respectively ) . These result create uncertainty regard minimal necessary duration antiplatelet therapy drug-eluting stent implantation . Also , remain widespread uncertainty regard risk clinical event discontinuation clopidogrel , particularly DES implantation .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1 . Among consecutive patient treat DES , eventfree patient survive least first 12 month without nonfatal MI repeat revascularization 2 . The patient guardian agrees study protocol schedule clinical followup , provide informed , write consent , approve appropriate Institutional Review Board/Ethical Committee respective clinical site . 1 . Contraindication antiplatelet therapy ( aspirin clopidogrel ) 2 . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) . 3 . Patients actively participate another drug device investigational study , complete primary endpoint followup period . 4 . Concurrent bleed diathesis major bleed history require discontinuation antiplatelet drug . 5 . Patients leave main stem stenosis ( &gt; 50 % visual estimate ) leave main stenting 6 . Concomitant disease require longterm use clopidogrel ( stroke , peripheral vascular disease , significant carotid a. disease , etc )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>coronary disease</keyword>
	<keyword>stent</keyword>
	<keyword>antiplatelet drug</keyword>
	<keyword>drug-eluting stent</keyword>
</DOC>